{"id":3772,"date":"2025-08-08T13:36:35","date_gmt":"2025-08-08T16:36:35","guid":{"rendered":"https:\/\/desertking.com\/dagnew-a-f-et-al-safety-and-immunogenicity-of-investigational-tuberculosis-vaccine-m72-as01e4-in-people-living-with-hiv-in-south-africa-an-observer-blinded-randomised-controlled-phase-2-trial\/"},"modified":"2026-11-10T23:48:28","modified_gmt":"2026-11-11T02:48:28","slug":"tuberculosis-vaccine-saponin-adjuvant-hiv-trial","status":"publish","type":"post","link":"https:\/\/desertking.com\/es\/tuberculosis-vaccine-saponin-adjuvant-hiv-trial\/","title":{"rendered":"Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV, 2025 Aug, 12(8):e546-e555."},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01<\/span><span style=\"font-weight: 400;\">E4<\/span><span style=\"font-weight: 400;\">\u00a0in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. <\/span><i><span style=\"font-weight: 400;\">Lancet HIV<\/span><\/i><span style=\"font-weight: 400;\">, 2025 Aug, 12(8):e546-e555. PMID: 40614747<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The study evaluated the safety, reactogenicity, and immunogenicity of two doses of the TB vaccine M72\/AS01 E\u20134 in over 400 HIV-positive adults in South Africa with well-controlled, virally suppressed HIV.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The vaccine was well tolerated, with mostly mild or moderate side effects such as injection-site pain, headache, and fatigue, and showed no serious adverse events related to vaccination. Importantly, it elicited strong antibody and T-cell responses, indicating a robust immune response, which was sustained through the end of the trial.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The paper describes QS-21 as a key component of the AS01 E\u20134 adjuvant system used in the M72\/AS01 E\u20134 tuberculosis vaccine. QS-21 is a saponin extract derived from Quillaja saponaria Molina, included at a dose of 25 \u03bcg per vaccine dose. The study reports that the vaccine, which contains QS-21, elicited robust antibody and CD4 T-cell responses, indicating that QS-21 contributes significantly to the vaccine\u2019s immunogenic profile. Additionally, the safety data suggest that inclusion of QS-21 does not compromise tolerability, as most adverse events were mild or moderate and transient.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">These findings support further testing of the vaccine in larger populations, including people living with HIV, to assess its effectiveness in preventing tuberculosis in this high-risk group.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Click <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40614747\/\" rel=\"nofollow noopener\" target=\"_blank\"><span style=\"font-weight: 400;\">here <\/span><\/a><span style=\"font-weight: 400;\">to access the full scientific paper.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">[arrow_forms id=&#8217;3298&#8242;]<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E4\u00a0in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV, 2025 Aug, 12(8):e546-e555. PMID: 40614747 The study evaluated the safety, reactogenicity, and immunogenicity of two doses of the TB vaccine M72\/AS01 E\u20134 in over 400 HIV-positive adults [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":3770,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"rs_blank_template":"","rs_page_bg_color":"","slide_template_v7":"","footnotes":""},"categories":[74,46],"tags":[],"class_list":["post-3772","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saponin-related-publications","category-texto-cientifico"],"_links":{"self":[{"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/posts\/3772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/comments?post=3772"}],"version-history":[{"count":1,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/posts\/3772\/revisions"}],"predecessor-version":[{"id":4574,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/posts\/3772\/revisions\/4574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/media\/3770"}],"wp:attachment":[{"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/media?parent=3772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/categories?post=3772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/desertking.com\/es\/wp-json\/wp\/v2\/tags?post=3772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}